White Paul A, Douglas George R, Phillips David H, Arlt Volker M
Environmental Health Science and Research Bureau, Health Canada, Tunney's Pasture 0803A, 50 Colombine Driveway, Ottawa, Ontario K1A 0K9, Canada and.
King's College London, Analytical and Environmental Sciences Division, MRC-PHE Centre for Environment and Health, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK.
Mutagenesis. 2017 Mar 1;32(2):299-312. doi: 10.1093/mutage/gew067.
The frequency of stable DNA adducts in a target tissue can be used to assess biologically effective dose; however, the utility of the metric in a risk assessment context depends on the likelihood that the DNA damage will be manifested as mutation. Previously, we employed the Muta™Mouse system to examine the induction of lacZ mutants and DNA adducts following exposure to the well-studied mutagenic carcinogen 3-nitrobenzanthrone (3-NBA). In this follow-up work, we examined the empirical relationships between total adduct frequency and mutant frequency (MF) in tissues and cultured cells following acute 3-NBA exposure. The results show a significant induction of DNA damage and lacZ mutants in liver, colon and bone marrow, as well as FE1 pulmonary epithelial cells. In contrast, lung and small intestine samples had low, but significantly elevated adduct levels, with no significant increases in lacZ MF. Additional analyses showed a significant relationship between the mutagenic efficiency of total adducts, measured as the slope of the relationships between MF and total adduct frequency, and tissue-specific mitotic index (MI). The lack of mutation response in lung, in contrast to the high in vitro MF in FE-1 lung cells, is likely related to the 100-fold difference in MI. The lack of small intestine mutagenic response may be related to limited metabolic capacity, differences in DNA repair, and /or chemically induced apoptosis that has been observed for other potent mutagens. The results indicate that interpretation of adduct frequency values in a risk assessment context can be improved by considering the MI of the target tissue; however, more generalised interpretation is hampered by tissue-specific variations in metabolic capacity and damage processing. The work provides a proof of principle regarding the use of the Muta™Mouse system to critically examine the health risks associated with tissue-specific adduct loads.
靶组织中稳定DNA加合物的频率可用于评估生物学有效剂量;然而,该指标在风险评估中的实用性取决于DNA损伤表现为突变的可能性。此前,我们使用Muta™Mouse系统研究了暴露于经过充分研究的诱变致癌物3-硝基苯并蒽(3-NBA)后lacZ突变体和DNA加合物的诱导情况。在这项后续工作中,我们研究了急性暴露于3-NBA后组织和培养细胞中总加合物频率与突变频率(MF)之间的经验关系。结果显示,肝脏、结肠、骨髓以及FE1肺上皮细胞中DNA损伤和lacZ突变体有显著诱导。相比之下,肺和小肠样本中的加合物水平较低,但显著升高,而lacZ MF没有显著增加。进一步分析表明,以MF与总加合物频率之间关系的斜率衡量的总加合物诱变效率与组织特异性有丝分裂指数(MI)之间存在显著关系。与FE-1肺细胞中较高的体外MF形成对比的是,肺中缺乏突变反应可能与MI相差100倍有关。小肠缺乏诱变反应可能与代谢能力有限、DNA修复差异和/或其他强效诱变剂所观察到的化学诱导凋亡有关。结果表明,在风险评估中考虑靶组织的MI可以改进对加合物频率值的解释;然而,代谢能力和损伤处理的组织特异性差异阻碍了更普遍的解释。这项工作为使用Muta™Mouse系统严格检查与组织特异性加合物负荷相关的健康风险提供了原理证明。